We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $11.7B
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
+36.75%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$1.05B
AUM Growth
+$452M
Cap. Flow
+$364M
Cap. Flow %
34.66%
Top 10 Hldgs %
71.51%
Holding
46
New
14
Increased
15
Reduced
8
Closed
8

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$244M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$45.9M
3
AGEN
Agenus
AGEN
+$22.6M
4
ARWR icon
Arrowhead Research
ARWR
+$18M
5
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$17.4M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$16.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$14.5M
3
OSUR icon
OraSure Technologies
OSUR
+$14.4M
4
ATRA icon
Atara Biotherapeutics
ATRA
+$10.1M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.07M

Sector Composition

Rank Sector Weight
1 Healthcare 99.76%
2 Miscellaneous 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$374M
$258M 24.57%
+14,969,744
New +$244M
PTCT icon
2
PTC Therapeutics
PTCT
$5.48B
$112M 10.66%
4,137,960
+7,845
+0.2% +$199K
BMY icon
3
Bristol-Myers Squibb
BMY
$130B
$69.3M 6.6%
1,096,386
+256,934
+31% +$16.5M
RGNX icon
4
Regenxbio
RGNX
$525M
$56.1M 5.33%
1,877,767
+316,557
+20% +$9.21M
SRPT icon
5
Sarepta Therapeutics
SRPT
$2.19B
$51M 4.85%
+688,271
New +$45.9M
ACHN
6
DELISTED
Achillion Pharmaceuticals
ACHN
$50.1M 4.77%
13,496,902
-50,000
-0.4% -$164K
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$48.1M 4.58%
5,029,462
-6,200
-0.1% -$66.8K
AGEN
8
Agenus
AGEN
$322M
$43.9M 4.17%
474,526
+253,922
+115% +$22.6M
LJPC
9
DELISTED
La Jolla Pharmaceutical Company
LJPC
$33.4M 3.18%
1,122,540
+59,370
+6% +$1.91M
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$31.9B
$29.3M 2.79%
246,229
-112,545
-31% -$14.5M
AVXS
11
DELISTED
AveXis, Inc. Common Stock
AVXS
$29.2M 2.78%
236,425
-44,817
-16% -$5.33M
ABUS icon
12
Arbutus Biopharma
ABUS
$1B
$25.8M 2.45%
5,151,615
– –
GBT
13
DELISTED
Global Blood Therapeutics, Inc.
GBT
$22.1M 2.1%
456,921
-144,762
-24% -$8.07M
CORI
14
DELISTED
Corium International, Inc.
CORI
$21.9M 2.09%
1,910,522
+210,869
+12% +$2.54M
ARWR icon
15
Arrowhead Research
ARWR
$9.98B
$21M 2%
+2,916,561
New +$18M
VCEL icon
16
Vericel Corp
VCEL
$2.03B
$20.6M 1.96%
2,067,916
+763,115
+58% +$6.31M
MASI
17
DELISTED
Masimo
MASI
$20.4M 1.94%
232,000
+111,100
+92% +$9.68M
EW icon
18
Edwards Lifesciences
EW
$49.4B
$20.3M 1.93%
435,738
+66,738
+18% +$2.9M
ARMO
19
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
$14M 1.33%
+413,892
New +$17.4M
MYOK
20
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$12.7M 1.21%
259,670
+2,007
+0.8% +$104K
LIVN icon
21
LivaNova
LIVN
$4.38B
$12.4M 1.18%
+140,000
New +$11.9M
QURE icon
22
uniQure
QURE
$2.99B
$9.56M 0.91%
406,667
+3,143
+0.8% +$68.5K
VIVE
23
DELISTED
VIVEVE MED INC
VIVE
$9.36M 0.89%
2,558
+885
+53% +$3.85M
VRAY
24
DELISTED
ViewRay, Inc.
VRAY
$8.74M 0.83%
1,358,711
+10,501
+0.8% +$87.5K
NVTR
25
DELISTED
Nuvectra Corporation Common Stock
NVTR
$6.6M 0.63%
+507,061
New +$5.15M
1
2

Similar funds

CIM
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

RTW Investments's Q1 2018 Portfolio in Review

As of Q1 2018, RTW Investments held 46 positions worth $1.05B, up 75% from $599M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

RTW Investments deployed $364M of net new capital in Q1 2018, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Rocket Pharmaceuticals: 14,969,744 shares worth $258M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $14.5M trimmed.

  • RTW Investments's largest Q1 2018 buy was Rocket Pharmaceuticals: 14,969,744 shares worth $258M.
  • RTW Investments added most to Agenus in Q1 2018, an estimated $22.6M increase.
  • RTW Investments's biggest Q1 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $14.5M.
  • RTW Investments fully exited BioCryst Pharmaceuticals in Q1 2018, selling an estimated $16.6M.
  • RTW Investments's ten largest holdings make up 72% of its $1.05B portfolio in Q1 2018.
  • RTW Investments opened 14 new positions and closed 8 in Q1 2018.
  • RTW Investments's portfolio value rose 75% quarter-over-quarter to $1.05B.

Based on RTW Investments's 13F filing for Q1 2018, filed 14 May 2018.